Overview
« Hide
More detailed introduction 
Immune checkpoint pathway blockade has revolutionized cancer treatment for some patients, with targeted immunotherapies including ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab making it to the clinic.
Subfamilies
|
Families that contain targets of relevance to immunopharmacology are highlighted in blue |
|
How to cite this family page
Database page citation:
Immune checkpoint proteins. Accessed on 16/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=954.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators. (2019) The Concise Guide to PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol. 176 Issue S1: S1-S20.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License